nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—Sudden death—Fluorouracil—head and neck cancer	0.0114	0.0162	CcSEcCtD
Acamprosate—Cardiomyopathy—Fluorouracil—head and neck cancer	0.0114	0.0162	CcSEcCtD
Acamprosate—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00987	0.014	CcSEcCtD
Acamprosate—Ascites—Docetaxel—head and neck cancer	0.00929	0.0132	CcSEcCtD
Acamprosate—Encephalopathy—Fluorouracil—head and neck cancer	0.00911	0.0129	CcSEcCtD
Acamprosate—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.00876	0.0124	CcSEcCtD
Acamprosate—Duodenal ulcer—Docetaxel—head and neck cancer	0.00874	0.0124	CcSEcCtD
Acamprosate—Creatinine increased—Hydroxyurea—head and neck cancer	0.00854	0.0121	CcSEcCtD
Acamprosate—GRIN2B—ErbB4 signaling events—YAP1—head and neck cancer	0.0084	0.0285	CbGpPWpGaD
Acamprosate—Photophobia—Vinblastine—head and neck cancer	0.00837	0.0119	CcSEcCtD
Acamprosate—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.00828	0.0117	CcSEcCtD
Acamprosate—Phlebitis—Vinblastine—head and neck cancer	0.00751	0.0107	CcSEcCtD
Acamprosate—GRM5—G alpha (q) signalling events—KISS1—head and neck cancer	0.00749	0.0253	CbGpPWpGaD
Acamprosate—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00739	0.0105	CcSEcCtD
Acamprosate—Deafness—Vinblastine—head and neck cancer	0.00723	0.0103	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00669	0.0227	CbGpPWpGaD
Acamprosate—Renal failure acute—Hydroxyurea—head and neck cancer	0.00639	0.00907	CcSEcCtD
Acamprosate—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.00617	0.00876	CcSEcCtD
Acamprosate—GRM5—G alpha (q) signalling events—GRP—head and neck cancer	0.00616	0.0209	CbGpPWpGaD
Acamprosate—Neuralgia—Docetaxel—head and neck cancer	0.00608	0.00862	CcSEcCtD
Acamprosate—Face oedema—Hydroxyurea—head and neck cancer	0.0057	0.00808	CcSEcCtD
Acamprosate—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.00553	0.00784	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00551	0.0187	CbGpPWpGaD
Acamprosate—Photophobia—Fluorouracil—head and neck cancer	0.00549	0.00779	CcSEcCtD
Acamprosate—Angina pectoris—Vinblastine—head and neck cancer	0.00545	0.00773	CcSEcCtD
Acamprosate—GRM5—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.00542	0.0184	CbGpPWpGaD
Acamprosate—Oesophagitis—Fluorouracil—head and neck cancer	0.00535	0.00759	CcSEcCtD
Acamprosate—Breast disorder—Hydroxyurea—head and neck cancer	0.00533	0.00757	CcSEcCtD
Acamprosate—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00532	0.00755	CcSEcCtD
Acamprosate—GRM5—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.00516	0.0175	CbGpPWpGaD
Acamprosate—Pancreatitis—Hydroxyurea—head and neck cancer	0.005	0.00709	CcSEcCtD
Acamprosate—Depression—Vinblastine—head and neck cancer	0.00497	0.00705	CcSEcCtD
Acamprosate—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00491	0.00697	CcSEcCtD
Acamprosate—Thrombophlebitis—Fluorouracil—head and neck cancer	0.00491	0.00696	CcSEcCtD
Acamprosate—Myocardial infarction—Vinblastine—head and neck cancer	0.00489	0.00694	CcSEcCtD
Acamprosate—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00464	0.00659	CcSEcCtD
Acamprosate—Weight increased—Hydroxyurea—head and neck cancer	0.00464	0.00659	CcSEcCtD
Acamprosate—Amnesia—Fluorouracil—head and neck cancer	0.00452	0.00641	CcSEcCtD
Acamprosate—Haemoglobin—Vinblastine—head and neck cancer	0.0045	0.00638	CcSEcCtD
Acamprosate—Haemorrhage—Vinblastine—head and neck cancer	0.00448	0.00635	CcSEcCtD
Acamprosate—Hypoaesthesia—Vinblastine—head and neck cancer	0.00445	0.00632	CcSEcCtD
Acamprosate—Dermatitis bullous—Fluorouracil—head and neck cancer	0.00444	0.00631	CcSEcCtD
Acamprosate—Pharyngitis—Vinblastine—head and neck cancer	0.00444	0.0063	CcSEcCtD
Acamprosate—Stomatitis—Hydroxyurea—head and neck cancer	0.00443	0.00629	CcSEcCtD
Acamprosate—Cardiac failure—Fluorouracil—head and neck cancer	0.00435	0.00618	CcSEcCtD
Acamprosate—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00425	0.00603	CcSEcCtD
Acamprosate—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00422	0.00599	CcSEcCtD
Acamprosate—Pulmonary embolism—Docetaxel—head and neck cancer	0.00422	0.00599	CcSEcCtD
Acamprosate—Haemoglobin—Hydroxyurea—head and neck cancer	0.0041	0.00582	CcSEcCtD
Acamprosate—Haemorrhage—Hydroxyurea—head and neck cancer	0.00408	0.00579	CcSEcCtD
Acamprosate—Hallucination—Hydroxyurea—head and neck cancer	0.00406	0.00576	CcSEcCtD
Acamprosate—Colitis—Docetaxel—head and neck cancer	0.00405	0.00575	CcSEcCtD
Acamprosate—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—head and neck cancer	0.00402	0.0136	CbGpPWpGaD
Acamprosate—Alopecia—Vinblastine—head and neck cancer	0.00395	0.00561	CcSEcCtD
Acamprosate—Dry skin—Fluorouracil—head and neck cancer	0.00389	0.00552	CcSEcCtD
Acamprosate—Oesophagitis—Docetaxel—head and neck cancer	0.00386	0.00548	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—KISS1—head and neck cancer	0.00378	0.0128	CbGpPWpGaD
Acamprosate—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—head and neck cancer	0.00374	0.0127	CbGpPWpGaD
Acamprosate—Dysphagia—Fluorouracil—head and neck cancer	0.00367	0.00521	CcSEcCtD
Acamprosate—Chills—Hydroxyurea—head and neck cancer	0.00366	0.0052	CcSEcCtD
Acamprosate—Eosinophilia—Fluorouracil—head and neck cancer	0.00363	0.00516	CcSEcCtD
Acamprosate—Ill-defined disorder—Vinblastine—head and neck cancer	0.00361	0.00513	CcSEcCtD
Acamprosate—Alopecia—Hydroxyurea—head and neck cancer	0.00361	0.00512	CcSEcCtD
Acamprosate—Anaemia—Vinblastine—head and neck cancer	0.0036	0.00511	CcSEcCtD
Acamprosate—Angina pectoris—Fluorouracil—head and neck cancer	0.00358	0.00507	CcSEcCtD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—MAPK1—head and neck cancer	0.00357	0.0121	CbGpPWpGaD
Acamprosate—Phlebitis—Docetaxel—head and neck cancer	0.00356	0.00505	CcSEcCtD
Acamprosate—Thrombophlebitis—Docetaxel—head and neck cancer	0.00354	0.00502	CcSEcCtD
Acamprosate—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.00352	0.005	CcSEcCtD
Acamprosate—Malaise—Vinblastine—head and neck cancer	0.00351	0.00499	CcSEcCtD
Acamprosate—Vertigo—Vinblastine—head and neck cancer	0.0035	0.00497	CcSEcCtD
Acamprosate—Leukopenia—Vinblastine—head and neck cancer	0.00349	0.00495	CcSEcCtD
Acamprosate—GRIN2C—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.00347	0.0117	CbGpPWpGaD
Acamprosate—Deafness—Docetaxel—head and neck cancer	0.00343	0.00486	CcSEcCtD
Acamprosate—Convulsion—Vinblastine—head and neck cancer	0.00338	0.00479	CcSEcCtD
Acamprosate—Hypertension—Vinblastine—head and neck cancer	0.00336	0.00477	CcSEcCtD
Acamprosate—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00335	0.00475	CcSEcCtD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—MAPK1—head and neck cancer	0.00332	0.0112	CbGpPWpGaD
Acamprosate—GRIN2C—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.0033	0.0112	CbGpPWpGaD
Acamprosate—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0033	0.00468	CcSEcCtD
Acamprosate—Pneumonia—Fluorouracil—head and neck cancer	0.00329	0.00467	CcSEcCtD
Acamprosate—Anaemia—Hydroxyurea—head and neck cancer	0.00328	0.00466	CcSEcCtD
Acamprosate—Discomfort—Vinblastine—head and neck cancer	0.00328	0.00465	CcSEcCtD
Acamprosate—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00323	0.00458	CcSEcCtD
Acamprosate—GRIN2D—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.00322	0.0109	CbGpPWpGaD
Acamprosate—Myocardial infarction—Fluorouracil—head and neck cancer	0.00321	0.00455	CcSEcCtD
Acamprosate—Dermatitis bullous—Docetaxel—head and neck cancer	0.00321	0.00455	CcSEcCtD
Acamprosate—Malaise—Hydroxyurea—head and neck cancer	0.0032	0.00455	CcSEcCtD
Acamprosate—Stomatitis—Fluorouracil—head and neck cancer	0.00319	0.00453	CcSEcCtD
Acamprosate—Urinary tract infection—Fluorouracil—head and neck cancer	0.00318	0.00451	CcSEcCtD
Acamprosate—Leukopenia—Hydroxyurea—head and neck cancer	0.00318	0.00451	CcSEcCtD
Acamprosate—Cardiac failure—Docetaxel—head and neck cancer	0.00314	0.00446	CcSEcCtD
Acamprosate—Thrombocytopenia—Vinblastine—head and neck cancer	0.00311	0.00442	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—GRP—head and neck cancer	0.00311	0.0105	CbGpPWpGaD
Acamprosate—Epistaxis—Fluorouracil—head and neck cancer	0.00309	0.00438	CcSEcCtD
Acamprosate—Convulsion—Hydroxyurea—head and neck cancer	0.00308	0.00437	CcSEcCtD
Acamprosate—Hyponatraemia—Docetaxel—head and neck cancer	0.00308	0.00437	CcSEcCtD
Acamprosate—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—head and neck cancer	0.00307	0.0104	CbGpPWpGaD
Acamprosate—GRIN2D—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.00307	0.0104	CbGpPWpGaD
Acamprosate—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00307	0.00435	CcSEcCtD
Acamprosate—Anorexia—Vinblastine—head and neck cancer	0.00303	0.0043	CcSEcCtD
Acamprosate—Migraine—Docetaxel—head and neck cancer	0.00302	0.00428	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.003	0.00426	CcSEcCtD
Acamprosate—Discomfort—Hydroxyurea—head and neck cancer	0.00299	0.00424	CcSEcCtD
Acamprosate—Haemoglobin—Fluorouracil—head and neck cancer	0.00295	0.00419	CcSEcCtD
Acamprosate—Rhinitis—Fluorouracil—head and neck cancer	0.00295	0.00418	CcSEcCtD
Acamprosate—Haemorrhage—Fluorouracil—head and neck cancer	0.00294	0.00417	CcSEcCtD
Acamprosate—GRIN2C—Post NMDA receptor activation events—MAPK1—head and neck cancer	0.00294	0.00995	CbGpPWpGaD
Acamprosate—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00292	0.00415	CcSEcCtD
Acamprosate—Pharyngitis—Fluorouracil—head and neck cancer	0.00292	0.00414	CcSEcCtD
Acamprosate—Infection—Hydroxyurea—head and neck cancer	0.00288	0.00409	CcSEcCtD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—head and neck cancer	0.00287	0.00971	CbGpPWpGaD
Acamprosate—Paraesthesia—Vinblastine—head and neck cancer	0.00286	0.00405	CcSEcCtD
Acamprosate—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00284	0.00403	CcSEcCtD
Acamprosate—Liver function test abnormal—Docetaxel—head and neck cancer	0.00283	0.00402	CcSEcCtD
Acamprosate—Skin disorder—Hydroxyurea—head and neck cancer	0.00282	0.004	CcSEcCtD
Acamprosate—Dry skin—Docetaxel—head and neck cancer	0.00281	0.00399	CcSEcCtD
Acamprosate—Orthostatic hypotension—Docetaxel—head and neck cancer	0.0028	0.00397	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—CASP8—head and neck cancer	0.00277	0.00938	CbGpPWpGaD
Acamprosate—Breast disorder—Docetaxel—head and neck cancer	0.00277	0.00393	CcSEcCtD
Acamprosate—Anorexia—Hydroxyurea—head and neck cancer	0.00276	0.00392	CcSEcCtD
Acamprosate—Decreased appetite—Vinblastine—head and neck cancer	0.00276	0.00392	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00276	0.00392	CcSEcCtD
Acamprosate—GRIN2D—Post NMDA receptor activation events—MAPK1—head and neck cancer	0.00273	0.00925	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—MAPK1—head and neck cancer	0.00273	0.00923	CbGpPWpGaD
Acamprosate—Pain—Vinblastine—head and neck cancer	0.00272	0.00386	CcSEcCtD
Acamprosate—Constipation—Vinblastine—head and neck cancer	0.00272	0.00386	CcSEcCtD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—MAPK1—head and neck cancer	0.00271	0.00916	CbGpPWpGaD
Acamprosate—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.0027	0.00384	CcSEcCtD
Acamprosate—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—head and neck cancer	0.00268	0.00906	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—head and neck cancer	0.00266	0.00902	CbGpPWpGaD
Acamprosate—Dysphagia—Docetaxel—head and neck cancer	0.00265	0.00376	CcSEcCtD
Acamprosate—GRIN2A—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.00265	0.00896	CbGpPWpGaD
Acamprosate—Feeling abnormal—Vinblastine—head and neck cancer	0.00262	0.00372	CcSEcCtD
Acamprosate—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—head and neck cancer	0.00261	0.00884	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Vinblastine—head and neck cancer	0.0026	0.00369	CcSEcCtD
Acamprosate—Alopecia—Fluorouracil—head and neck cancer	0.0026	0.00368	CcSEcCtD
Acamprosate—Dyspnoea—Hydroxyurea—head and neck cancer	0.00259	0.00367	CcSEcCtD
Acamprosate—Angina pectoris—Docetaxel—head and neck cancer	0.00258	0.00366	CcSEcCtD
Acamprosate—Somnolence—Hydroxyurea—head and neck cancer	0.00258	0.00366	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—CASP8—head and neck cancer	0.00258	0.00872	CbGpPWpGaD
Acamprosate—Dyspepsia—Hydroxyurea—head and neck cancer	0.00255	0.00362	CcSEcCtD
Acamprosate—GABRB3—Ion channel transport—ATP7B—head and neck cancer	0.00254	0.00859	CbGpPWpGaD
Acamprosate—Decreased appetite—Hydroxyurea—head and neck cancer	0.00252	0.00358	CcSEcCtD
Acamprosate—GRIN2A—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.00252	0.00853	CbGpPWpGaD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—MAPK1—head and neck cancer	0.00252	0.00852	CbGpPWpGaD
Acamprosate—Abdominal pain—Vinblastine—head and neck cancer	0.00251	0.00357	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.0025	0.00355	CcSEcCtD
Acamprosate—GABRG2—Ion channel transport—ATP7B—head and neck cancer	0.00249	0.00844	CbGpPWpGaD
Acamprosate—Pain—Hydroxyurea—head and neck cancer	0.00248	0.00352	CcSEcCtD
Acamprosate—Constipation—Hydroxyurea—head and neck cancer	0.00248	0.00352	CcSEcCtD
Acamprosate—GRIN2A—Reelin signaling pathway—PIK3CA—head and neck cancer	0.00243	0.00824	CbGpPWpGaD
Acamprosate—Weight increased—Docetaxel—head and neck cancer	0.00241	0.00342	CcSEcCtD
Acamprosate—Weight decreased—Docetaxel—head and neck cancer	0.0024	0.0034	CcSEcCtD
Acamprosate—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00239	0.00339	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00238	0.00807	CbGpPWpGaD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—MAPK1—head and neck cancer	0.00238	0.00805	CbGpPWpGaD
Acamprosate—Pneumonia—Docetaxel—head and neck cancer	0.00238	0.00337	CcSEcCtD
Acamprosate—Anaemia—Fluorouracil—head and neck cancer	0.00236	0.00335	CcSEcCtD
Acamprosate—GRIN2C—Post NMDA receptor activation events—HRAS—head and neck cancer	0.00236	0.00799	CbGpPWpGaD
Acamprosate—Hypersensitivity—Vinblastine—head and neck cancer	0.00234	0.00332	CcSEcCtD
Acamprosate—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00233	0.0033	CcSEcCtD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—MAPK1—head and neck cancer	0.00232	0.00785	CbGpPWpGaD
Acamprosate—Myocardial infarction—Docetaxel—head and neck cancer	0.00232	0.00329	CcSEcCtD
Acamprosate—GRIN1—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.00231	0.00782	CbGpPWpGaD
Acamprosate—Stomatitis—Docetaxel—head and neck cancer	0.0023	0.00327	CcSEcCtD
Acamprosate—Body temperature increased—Hydroxyurea—head and neck cancer	0.00229	0.00325	CcSEcCtD
Acamprosate—Leukopenia—Fluorouracil—head and neck cancer	0.00229	0.00325	CcSEcCtD
Acamprosate—Asthenia—Vinblastine—head and neck cancer	0.00228	0.00324	CcSEcCtD
Acamprosate—GRIN2B—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.00225	0.00762	CbGpPWpGaD
Acamprosate—GRIN2A—Post NMDA receptor activation events—MAPK1—head and neck cancer	0.00224	0.00759	CbGpPWpGaD
Acamprosate—Epistaxis—Docetaxel—head and neck cancer	0.00223	0.00316	CcSEcCtD
Acamprosate—Convulsion—Fluorouracil—head and neck cancer	0.00222	0.00314	CcSEcCtD
Acamprosate—GRIN1—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.0022	0.00744	CbGpPWpGaD
Acamprosate—GRIN2D—Post NMDA receptor activation events—HRAS—head and neck cancer	0.00219	0.00742	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—head and neck cancer	0.00219	0.00741	CbGpPWpGaD
Acamprosate—GABRA1—Ion channel transport—ATP7B—head and neck cancer	0.00218	0.00738	CbGpPWpGaD
Acamprosate—Chest pain—Fluorouracil—head and neck cancer	0.00218	0.00309	CcSEcCtD
Acamprosate—Myalgia—Fluorouracil—head and neck cancer	0.00218	0.00309	CcSEcCtD
Acamprosate—Diarrhoea—Vinblastine—head and neck cancer	0.00218	0.00309	CcSEcCtD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.00217	0.00736	CbGpPWpGaD
Acamprosate—Discomfort—Fluorouracil—head and neck cancer	0.00215	0.00305	CcSEcCtD
Acamprosate—GRIN2B—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.00214	0.00725	CbGpPWpGaD
Acamprosate—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00214	0.00303	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—KISS1—head and neck cancer	0.00213	0.00722	CbGpPWpGaD
Acamprosate—Haemoglobin—Docetaxel—head and neck cancer	0.00213	0.00302	CcSEcCtD
Acamprosate—Rhinitis—Docetaxel—head and neck cancer	0.00213	0.00302	CcSEcCtD
Acamprosate—Haemorrhage—Docetaxel—head and neck cancer	0.00212	0.00301	CcSEcCtD
Acamprosate—Hepatitis—Docetaxel—head and neck cancer	0.00212	0.00301	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—CASP8—head and neck cancer	0.00212	0.00716	CbGpPWpGaD
Acamprosate—Hypoaesthesia—Docetaxel—head and neck cancer	0.00211	0.00299	CcSEcCtD
Acamprosate—Confusional state—Fluorouracil—head and neck cancer	0.0021	0.00299	CcSEcCtD
Acamprosate—Pharyngitis—Docetaxel—head and neck cancer	0.0021	0.00299	CcSEcCtD
Acamprosate—Dizziness—Vinblastine—head and neck cancer	0.0021	0.00298	CcSEcCtD
Acamprosate—GRIN2B—ErbB4 signaling events—MAPK3—head and neck cancer	0.0021	0.0071	CbGpPWpGaD
Acamprosate—Oedema peripheral—Docetaxel—head and neck cancer	0.00209	0.00296	CcSEcCtD
Acamprosate—Anaphylactic shock—Fluorouracil—head and neck cancer	0.00209	0.00296	CcSEcCtD
Acamprosate—Asthenia—Hydroxyurea—head and neck cancer	0.00208	0.00295	CcSEcCtD
Acamprosate—Infection—Fluorouracil—head and neck cancer	0.00207	0.00294	CcSEcCtD
Acamprosate—GRIN2B—Reelin signaling pathway—PIK3CA—head and neck cancer	0.00207	0.007	CbGpPWpGaD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—MAPK1—head and neck cancer	0.00207	0.007	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00204	0.0029	CcSEcCtD
Acamprosate—Visual impairment—Docetaxel—head and neck cancer	0.00204	0.0029	CcSEcCtD
Acamprosate—Tachycardia—Fluorouracil—head and neck cancer	0.00204	0.00289	CcSEcCtD
Acamprosate—Vomiting—Vinblastine—head and neck cancer	0.00202	0.00287	CcSEcCtD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.00202	0.00684	CbGpPWpGaD
Acamprosate—GRIN2B—ErbB4 signaling events—MAPK1—head and neck cancer	0.00199	0.00675	CbGpPWpGaD
Acamprosate—Headache—Vinblastine—head and neck cancer	0.00199	0.00283	CcSEcCtD
Acamprosate—Anorexia—Fluorouracil—head and neck cancer	0.00199	0.00282	CcSEcCtD
Acamprosate—GRIN2A—Reelin signaling pathway—AKT1—head and neck cancer	0.00199	0.00673	CbGpPWpGaD
Acamprosate—Diarrhoea—Hydroxyurea—head and neck cancer	0.00198	0.00282	CcSEcCtD
Acamprosate—GRIN1—Post NMDA receptor activation events—MAPK1—head and neck cancer	0.00196	0.00662	CbGpPWpGaD
Acamprosate—Hypotension—Fluorouracil—head and neck cancer	0.00195	0.00277	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—KISS1—head and neck cancer	0.00194	0.00656	CbGpPWpGaD
Acamprosate—Dizziness—Hydroxyurea—head and neck cancer	0.00192	0.00272	CcSEcCtD
Acamprosate—Immune system disorder—Docetaxel—head and neck cancer	0.00192	0.00272	CcSEcCtD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—head and neck cancer	0.00191	0.00646	CbGpPWpGaD
Acamprosate—GRIN2B—Post NMDA receptor activation events—MAPK1—head and neck cancer	0.00191	0.00646	CbGpPWpGaD
Acamprosate—Chills—Docetaxel—head and neck cancer	0.0019	0.0027	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.0019	0.0027	CcSEcCtD
Acamprosate—Nausea—Vinblastine—head and neck cancer	0.00189	0.00268	CcSEcCtD
Acamprosate—Insomnia—Fluorouracil—head and neck cancer	0.00189	0.00268	CcSEcCtD
Acamprosate—Paraesthesia—Fluorouracil—head and neck cancer	0.00187	0.00266	CcSEcCtD
Acamprosate—Alopecia—Docetaxel—head and neck cancer	0.00187	0.00266	CcSEcCtD
Acamprosate—Dyspnoea—Fluorouracil—head and neck cancer	0.00186	0.00264	CcSEcCtD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—head and neck cancer	0.00186	0.0063	CbGpPWpGaD
Acamprosate—Mental disorder—Docetaxel—head and neck cancer	0.00186	0.00264	CcSEcCtD
Acamprosate—Somnolence—Fluorouracil—head and neck cancer	0.00186	0.00263	CcSEcCtD
Acamprosate—Malnutrition—Docetaxel—head and neck cancer	0.00185	0.00262	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—CASP8—head and neck cancer	0.00184	0.00625	CbGpPWpGaD
Acamprosate—Vomiting—Hydroxyurea—head and neck cancer	0.00184	0.00262	CcSEcCtD
Acamprosate—Dyspepsia—Fluorouracil—head and neck cancer	0.00184	0.00261	CcSEcCtD
Acamprosate—Rash—Hydroxyurea—head and neck cancer	0.00183	0.00259	CcSEcCtD
Acamprosate—Dermatitis—Hydroxyurea—head and neck cancer	0.00183	0.00259	CcSEcCtD
Acamprosate—Headache—Hydroxyurea—head and neck cancer	0.00182	0.00258	CcSEcCtD
Acamprosate—Decreased appetite—Fluorouracil—head and neck cancer	0.00181	0.00257	CcSEcCtD
Acamprosate—Dysgeusia—Docetaxel—head and neck cancer	0.00181	0.00257	CcSEcCtD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—MAPK1—head and neck cancer	0.0018	0.0061	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.0018	0.00256	CcSEcCtD
Acamprosate—GRIN2A—Post NMDA receptor activation events—HRAS—head and neck cancer	0.0018	0.0061	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—CASP8—head and neck cancer	0.0018	0.00609	CbGpPWpGaD
Acamprosate—Back pain—Docetaxel—head and neck cancer	0.00179	0.00253	CcSEcCtD
Acamprosate—Pain—Fluorouracil—head and neck cancer	0.00178	0.00253	CcSEcCtD
Acamprosate—Muscle spasms—Docetaxel—head and neck cancer	0.00177	0.00252	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—GRP—head and neck cancer	0.00176	0.00595	CbGpPWpGaD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—MAPK1—head and neck cancer	0.00176	0.00595	CbGpPWpGaD
Acamprosate—GRIN2B—ErbB4 signaling events—PIK3CA—head and neck cancer	0.00173	0.00586	CbGpPWpGaD
Acamprosate—Nausea—Hydroxyurea—head and neck cancer	0.00172	0.00244	CcSEcCtD
Acamprosate—Feeling abnormal—Fluorouracil—head and neck cancer	0.00172	0.00244	CcSEcCtD
Acamprosate—Anaemia—Docetaxel—head and neck cancer	0.00171	0.00242	CcSEcCtD
Acamprosate—GRIN2B—Reelin signaling pathway—AKT1—head and neck cancer	0.00169	0.00572	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—MAPK3—head and neck cancer	0.00168	0.0057	CbGpPWpGaD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.00166	0.00562	CbGpPWpGaD
Acamprosate—Urticaria—Fluorouracil—head and neck cancer	0.00166	0.00235	CcSEcCtD
Acamprosate—Syncope—Docetaxel—head and neck cancer	0.00166	0.00235	CcSEcCtD
Acamprosate—Leukopenia—Docetaxel—head and neck cancer	0.00165	0.00234	CcSEcCtD
Acamprosate—Body temperature increased—Fluorouracil—head and neck cancer	0.00165	0.00234	CcSEcCtD
Acamprosate—Palpitations—Docetaxel—head and neck cancer	0.00163	0.00231	CcSEcCtD
Acamprosate—Loss of consciousness—Docetaxel—head and neck cancer	0.00162	0.0023	CcSEcCtD
Acamprosate—Cough—Docetaxel—head and neck cancer	0.00161	0.00229	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—MAPK1—head and neck cancer	0.0016	0.00542	CbGpPWpGaD
Acamprosate—Convulsion—Docetaxel—head and neck cancer	0.0016	0.00227	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—GRP—head and neck cancer	0.0016	0.0054	CbGpPWpGaD
Acamprosate—Hypertension—Docetaxel—head and neck cancer	0.00159	0.00226	CcSEcCtD
Acamprosate—Myalgia—Docetaxel—head and neck cancer	0.00157	0.00223	CcSEcCtD
Acamprosate—Chest pain—Docetaxel—head and neck cancer	0.00157	0.00223	CcSEcCtD
Acamprosate—Arthralgia—Docetaxel—head and neck cancer	0.00157	0.00223	CcSEcCtD
Acamprosate—GRIN1—Post NMDA receptor activation events—HRAS—head and neck cancer	0.00157	0.00532	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—MAPK3—head and neck cancer	0.00156	0.0053	CbGpPWpGaD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00156	0.00221	CcSEcCtD
Acamprosate—Hypersensitivity—Fluorouracil—head and neck cancer	0.00154	0.00218	CcSEcCtD
Acamprosate—Dry mouth—Docetaxel—head and neck cancer	0.00154	0.00218	CcSEcCtD
Acamprosate—GRIN2B—Post NMDA receptor activation events—HRAS—head and neck cancer	0.00153	0.00518	CbGpPWpGaD
Acamprosate—Confusional state—Docetaxel—head and neck cancer	0.00152	0.00216	CcSEcCtD
Acamprosate—Anaphylactic shock—Docetaxel—head and neck cancer	0.00151	0.00214	CcSEcCtD
Acamprosate—Infection—Docetaxel—head and neck cancer	0.0015	0.00212	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—MAPK1—head and neck cancer	0.00149	0.00504	CbGpPWpGaD
Acamprosate—Shock—Docetaxel—head and neck cancer	0.00148	0.0021	CcSEcCtD
Acamprosate—Pruritus—Fluorouracil—head and neck cancer	0.00148	0.0021	CcSEcCtD
Acamprosate—Thrombocytopenia—Docetaxel—head and neck cancer	0.00148	0.00209	CcSEcCtD
Acamprosate—Tachycardia—Docetaxel—head and neck cancer	0.00147	0.00209	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—CEBPA—head and neck cancer	0.00147	0.00496	CbGpPWpGaD
Acamprosate—Skin disorder—Docetaxel—head and neck cancer	0.00146	0.00208	CcSEcCtD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.00145	0.0049	CbGpPWpGaD
Acamprosate—GRIN1—EPHB-mediated forward signaling—HRAS—head and neck cancer	0.00145	0.0049	CbGpPWpGaD
Acamprosate—Anorexia—Docetaxel—head and neck cancer	0.00144	0.00204	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—CEBPA—head and neck cancer	0.00143	0.00484	CbGpPWpGaD
Acamprosate—Diarrhoea—Fluorouracil—head and neck cancer	0.00143	0.00203	CcSEcCtD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—head and neck cancer	0.00141	0.00478	CbGpPWpGaD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—HRAS—head and neck cancer	0.00141	0.00478	CbGpPWpGaD
Acamprosate—Hypotension—Docetaxel—head and neck cancer	0.00141	0.002	CcSEcCtD
Acamprosate—Dizziness—Fluorouracil—head and neck cancer	0.00138	0.00196	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00137	0.00195	CcSEcCtD
Acamprosate—Insomnia—Docetaxel—head and neck cancer	0.00136	0.00193	CcSEcCtD
Acamprosate—Paraesthesia—Docetaxel—head and neck cancer	0.00135	0.00192	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—head and neck cancer	0.00134	0.00455	CbGpPWpGaD
Acamprosate—Dyspnoea—Docetaxel—head and neck cancer	0.00134	0.00191	CcSEcCtD
Acamprosate—Somnolence—Docetaxel—head and neck cancer	0.00134	0.0019	CcSEcCtD
Acamprosate—Vomiting—Fluorouracil—head and neck cancer	0.00133	0.00188	CcSEcCtD
Acamprosate—Dyspepsia—Docetaxel—head and neck cancer	0.00133	0.00188	CcSEcCtD
Acamprosate—Rash—Fluorouracil—head and neck cancer	0.00132	0.00187	CcSEcCtD
Acamprosate—Dermatitis—Fluorouracil—head and neck cancer	0.00131	0.00187	CcSEcCtD
Acamprosate—Decreased appetite—Docetaxel—head and neck cancer	0.00131	0.00186	CcSEcCtD
Acamprosate—Headache—Fluorouracil—head and neck cancer	0.00131	0.00186	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.0013	0.00185	CcSEcCtD
Acamprosate—Constipation—Docetaxel—head and neck cancer	0.00129	0.00183	CcSEcCtD
Acamprosate—Pain—Docetaxel—head and neck cancer	0.00129	0.00183	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—MAPK3—head and neck cancer	0.00128	0.00435	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—head and neck cancer	0.00125	0.00423	CbGpPWpGaD
Acamprosate—Feeling abnormal—Docetaxel—head and neck cancer	0.00124	0.00176	CcSEcCtD
Acamprosate—Nausea—Fluorouracil—head and neck cancer	0.00124	0.00176	CcSEcCtD
Acamprosate—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00123	0.00175	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—MAPK1—head and neck cancer	0.00122	0.00414	CbGpPWpGaD
Acamprosate—Abdominal pain—Docetaxel—head and neck cancer	0.00119	0.00169	CcSEcCtD
Acamprosate—Body temperature increased—Docetaxel—head and neck cancer	0.00119	0.00169	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.00118	0.004	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KISS1—head and neck cancer	0.00114	0.00388	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.00112	0.00381	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.00112	0.0038	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—MAPK3—head and neck cancer	0.00112	0.00379	CbGpPWpGaD
Acamprosate—Hypersensitivity—Docetaxel—head and neck cancer	0.00111	0.00158	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—MAPK3—head and neck cancer	0.00109	0.0037	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—PTGS2—head and neck cancer	0.00109	0.00369	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.00109	0.00369	CbGpPWpGaD
Acamprosate—Asthenia—Docetaxel—head and neck cancer	0.00108	0.00153	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—MAPK1—head and neck cancer	0.00107	0.00361	CbGpPWpGaD
Acamprosate—Pruritus—Docetaxel—head and neck cancer	0.00107	0.00151	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—MAPK1—head and neck cancer	0.00104	0.00352	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—VEGFA—head and neck cancer	0.00103	0.00349	CbGpPWpGaD
Acamprosate—Diarrhoea—Docetaxel—head and neck cancer	0.00103	0.00146	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—head and neck cancer	0.00103	0.00348	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.00101	0.00343	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—IL2—head and neck cancer	0.00101	0.00342	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—VEGFA—head and neck cancer	0.001	0.0034	CbGpPWpGaD
Acamprosate—Dizziness—Docetaxel—head and neck cancer	0.000996	0.00141	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—CCND1—head and neck cancer	0.000986	0.00334	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000975	0.0033	CbGpPWpGaD
Acamprosate—Vomiting—Docetaxel—head and neck cancer	0.000958	0.00136	CcSEcCtD
Acamprosate—Rash—Docetaxel—head and neck cancer	0.00095	0.00135	CcSEcCtD
Acamprosate—Dermatitis—Docetaxel—head and neck cancer	0.000949	0.00135	CcSEcCtD
Acamprosate—Headache—Docetaxel—head and neck cancer	0.000944	0.00134	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—GRP—head and neck cancer	0.000942	0.00319	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000942	0.00319	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—STAT6—head and neck cancer	0.000915	0.0031	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000902	0.00305	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—TP53—head and neck cancer	0.000895	0.00303	CbGpPWpGaD
Acamprosate—Nausea—Docetaxel—head and neck cancer	0.000895	0.00127	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000883	0.00299	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—head and neck cancer	0.000873	0.00295	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000867	0.00294	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000813	0.00275	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—MAPK3—head and neck cancer	0.000813	0.00275	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—YAP1—head and neck cancer	0.00081	0.00274	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—MAPK1—head and neck cancer	0.000774	0.00262	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000773	0.00262	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—EGFR—head and neck cancer	0.000773	0.00262	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000762	0.00258	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000758	0.00257	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000756	0.00256	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—HRAS—head and neck cancer	0.000745	0.00252	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—HRAS—head and neck cancer	0.000726	0.00246	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—STAT3—head and neck cancer	0.000726	0.00246	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000708	0.0024	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—STAT3—head and neck cancer	0.000707	0.0024	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—MAPK3—head and neck cancer	0.000693	0.00235	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000687	0.00233	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—MAPK3—head and neck cancer	0.000676	0.00229	CbGpPWpGaD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000675	0.00228	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—MAPK1—head and neck cancer	0.00066	0.00223	CbGpPWpGaD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000658	0.00223	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—head and neck cancer	0.000649	0.0022	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—MAPK1—head and neck cancer	0.000643	0.00218	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000621	0.0021	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000611	0.00207	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—MAPK1—head and neck cancer	0.000584	0.00198	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000581	0.00197	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000568	0.00192	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—MAPK1—head and neck cancer	0.000543	0.00184	CbGpPWpGaD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000542	0.00183	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—HRAS—head and neck cancer	0.00053	0.00179	CbGpPWpGaD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000528	0.00179	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—HRAS—head and neck cancer	0.000516	0.00175	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000507	0.00172	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000494	0.00167	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—STAT3—head and neck cancer	0.000479	0.00162	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—HRAS—head and neck cancer	0.000469	0.00159	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—IL2—head and neck cancer	0.000468	0.00159	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—AKT1—head and neck cancer	0.000468	0.00158	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—NOTCH1—head and neck cancer	0.000467	0.00158	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000467	0.00158	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—MAPK3—head and neck cancer	0.000457	0.00155	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—AKT1—head and neck cancer	0.000456	0.00154	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—NOTCH1—head and neck cancer	0.000456	0.00154	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—MAPK1—head and neck cancer	0.000446	0.00151	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000445	0.00151	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000437	0.00148	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—HRAS—head and neck cancer	0.000436	0.00147	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—MAPK1—head and neck cancer	0.000435	0.00147	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL2—head and neck cancer	0.000425	0.00144	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000407	0.00138	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000397	0.00134	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000389	0.00132	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—MAPK1—head and neck cancer	0.000389	0.00132	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—VEGFA—head and neck cancer	0.000383	0.0013	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—head and neck cancer	0.000382	0.00129	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—MAPK1—head and neck cancer	0.000379	0.00128	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—VEGFA—head and neck cancer	0.000373	0.00126	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NOTCH1—head and neck cancer	0.000365	0.00124	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MAPK3—head and neck cancer	0.000362	0.00123	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—HRAS—head and neck cancer	0.000358	0.00121	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000357	0.00121	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MAPK3—head and neck cancer	0.000353	0.0012	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000351	0.00119	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—HRAS—head and neck cancer	0.000349	0.00118	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MAPK1—head and neck cancer	0.000345	0.00117	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—EGFR—head and neck cancer	0.000345	0.00117	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—MAPK3—head and neck cancer	0.000342	0.00116	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MAPK1—head and neck cancer	0.000336	0.00114	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—EGFR—head and neck cancer	0.000336	0.00114	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000335	0.00113	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000329	0.00111	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—MAPK1—head and neck cancer	0.000325	0.0011	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—EGFR—head and neck cancer	0.000325	0.0011	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—HRAS—head and neck cancer	0.000312	0.00106	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000311	0.00105	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—AKT1—head and neck cancer	0.000308	0.00104	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—head and neck cancer	0.000307	0.00104	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—HRAS—head and neck cancer	0.000304	0.00103	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—MAPK1—head and neck cancer	0.000287	0.000972	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PIK3CA—head and neck cancer	0.000282	0.000956	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—HRAS—head and neck cancer	0.000277	0.000937	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—VEGFA—head and neck cancer	0.000273	0.000926	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—STAT3—head and neck cancer	0.000271	0.000917	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—HRAS—head and neck cancer	0.00027	0.000914	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000269	0.00091	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—VEGFA—head and neck cancer	0.000266	0.000902	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—STAT3—head and neck cancer	0.000264	0.000893	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000264	0.000893	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—HRAS—head and neck cancer	0.000261	0.000884	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MAPK3—head and neck cancer	0.000259	0.000876	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—MAPK1—head and neck cancer	0.000256	0.000868	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—AKT1—head and neck cancer	0.000254	0.00086	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MAPK3—head and neck cancer	0.000252	0.000854	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—MAPK1—head and neck cancer	0.000252	0.000852	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IL2—head and neck cancer	0.000251	0.00085	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MAPK1—head and neck cancer	0.000246	0.000833	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EGFR—head and neck cancer	0.000246	0.000833	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CCND1—head and neck cancer	0.000245	0.000829	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MAPK1—head and neck cancer	0.00024	0.000812	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EGFR—head and neck cancer	0.00024	0.000812	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTEN—head and neck cancer	0.000236	0.0008	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—HRAS—head and neck cancer	0.000231	0.000781	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—AKT1—head and neck cancer	0.000231	0.000781	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—MAPK1—head and neck cancer	0.00022	0.000745	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—VEGFA—head and neck cancer	0.000213	0.000723	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—STAT3—head and neck cancer	0.000211	0.000716	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—HRAS—head and neck cancer	0.000206	0.000697	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—HRAS—head and neck cancer	0.000202	0.000684	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MAPK3—head and neck cancer	0.000202	0.000684	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—HRAS—head and neck cancer	0.000198	0.000669	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—HRAS—head and neck cancer	0.000193	0.000652	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MAPK1—head and neck cancer	0.000192	0.00065	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EGFR—head and neck cancer	0.000192	0.00065	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—HRAS—head and neck cancer	0.000177	0.000598	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—AKT1—head and neck cancer	0.000174	0.000591	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—AKT1—head and neck cancer	0.00017	0.000576	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CA—head and neck cancer	0.000167	0.000564	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—head and neck cancer	0.000161	0.000546	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HRAS—head and neck cancer	0.000154	0.000522	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKT1—head and neck cancer	0.000136	0.000461	CbGpPWpGaD
